Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 40, 2012, Pages

  Schulz, Martin Michael Peter ^a   Reisen, Felix ^a   Zgraggen, Silvana ^a   Fischer, Stephanie ^a   Yuen, Don ^b   Kang, Gyeong Jin ^b   Chen, Lu ^b   Schneider, Gisbert ^a   Detmar, Michael ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemical genetics; High content screening; Lymphatic endothelium; Small compound screening

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOGENESIS INHIBITOR; ATOMOXETINE; ATORVASTATIN; BIX 01289; CALCIMYCIN; CAMPTOTHECIN; COLCHICINE; COMPACTIN; DIHYDROOUABAIN; DIPHENYLIODONIUM SALT; DISULFIRAM; FLUSPIRILENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IC 261; IDARUBICIN; INDIRUBIN 3' OXIME; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOXANTRONE; PACLITAXEL; PODOPHYLLOTOXIN; PROPIONYLPROMAZINE HYDROCHLORIDE; RDEA 119; SANGUINARINE; SEMAXANIB; SIMVASTATIN; SUNITINIB; THAPSIGARGIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTOMATION; CELL ASSAY; CELL MEMBRANE; COMPUTER PROGRAM; CONTROLLED STUDY; CORNEA; DRUG SCREENING; ENDOTHELIUM CELL; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE PROCESSING; IN VITRO STUDY; IN VIVO STUDY; ISOPRENYLATION; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MOLECULAR LIBRARY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION; SKIN;

ANALYSIS OF VARIANCE; ENDOTHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOBLOTTING; LYMPHANGIOGENESIS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84867055688     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206036109     Document Type: Article

References (46)

1. Christiansen A, Detmar M (2011) Lymphangiogenesis and cancer. Genes Cancer 2:1146-1158.
2. Dadras SS, et al. (2003) Tumor lymphangiogenesis: A novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162:1951-1960. (Pubitemid 36613052)
3. Hirakawa S, et al. (2005) VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201:1089-1099. (Pubitemid 40524677)
4. Kim M, et al. (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70:10411-10421.
5. Jurisic G, Detmar M (2009) Lymphatic endothelium in health and disease. Cell Tissue Res 335:97-108.
6. Skobe M, et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192-198. (Pubitemid 32148486)
7. Hirakawa S, et al. (2007) VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109:1010-1017. (Pubitemid 46220646)
8. Caunt M, et al. (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13:331-342. (Pubitemid 351446192)
9. Zheng W, et al. (2011) Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood 118:1154-1162.
10. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507-519.
11. Frémin C, Meloche S (2010) From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3:8.
12. Hirakawa S, et al. (2003) Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 162:575-586. (Pubitemid 36267864)
13. Shin JW, Huggenberger R, Detmar M (2008) Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 112:2318-2326.
14. Jurisic G, Iolyeva M, Proulx ST, Halin C, Detmar M (2010) Thymus cell antigen 1 (Thy1, CD90) is expressed by lymphatic vessels and mediates cell adhesion to lymphatic endothelium. Exp Cell Res 316:2982-2992.
15. Yuen D, Pytowski B, Chen L (2011) Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages. Invest Ophthalmol Vis Sci 52:2593-2597.
16. Chong CR, et al. (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2:263-270.
17. Evensen L, Micklem DR, LinkW, Lorens JB (2010) A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry A 77:41-51.
18. Sanz L, et al. (2002) Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing. Microvasc Res 63:335-339. (Pubitemid 34971629)
19. Kalén M, et al. (2009) Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets. Chem Biol 16:432-441.
20. Bruyère F, et al. (2008) Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 5:431-437. (Pubitemid 351619102)
21. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478. (Pubitemid 46823443)
22. Nehls V, Drenckhahn D (1995) A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 50:311-322.
23. Nakatsu M, Hughes C (2008) An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol 443:65-82.
24. Xu Y, et al. (2010) Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol 188:115-130.
25. Pitulescu ME, Schmidt I, Benedito R, Adams RH (2010) Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat Protoc 5:1518-1534.
26. Kerjaschki D, et al. (2011) Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest 121:2000-2012.
27. 2+ signaling pathways. Blood 112:1129-1138.
28. Bayless KJ, Kwak H-I, Su S-C (2009) Investigating endothelial invasion and sprouting behavior in three-dimensional collagen matrices. Nat Protoc 4:1888-1898.
29. Wang C, et al. (2010) Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 58:418-426.
30. Tran TC, et al. (2007) Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 67:11386-11392. (Pubitemid 350248566)
31. Kälin RE, Bänziger-Tobler NE, Detmar M, Brändli AW(2009) An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis. Blood 114:1110-1122.
32. Peterson RT, Fishman MC (2004) Discovery and use of small molecules for probing biological processes in zebrafish. Methods Cell Biol 76:569-591.
33. Berghmans S, et al. (2008) Zebrafish based assays for the assessment of cardiac, visual and gut function: Potential safety screens for early drug discovery. J Pharmacol Toxicol Methods 58:59-68.
34. Santos AF, et al. (2008) Angiogenesis: An improved in vitro biological system and automated image-based workflow to aid identification and characterization of angiogenesis and angiogenic modulators. Assay Drug Dev Technol 6:693-710.
35. Gibbs RA, et al. (2004) Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428:493-521.
36. Iverson C, et al. (2009) RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 69:6839-6847.
37. Tatake RJ, et al. (2008) Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun 377:120-125.
38. Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11:306-315.
39. Ridker PM, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207.
40. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM (2011) Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 103:885-892.
41. Poynter JN, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192. (Pubitemid 40727085)
42. Park H-J, et al. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91:143-150. (Pubitemid 34827225)
43. Singh NK, Kundumani-Sridharan V, Rao GN (2011) 12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation. Blood 118:5701-5712.
44. Fröhlich GM, et al. (2012) Statins and the risk of cancer after heart transplantation. Circulation 126:440-447.
45. Vincent L, et al. (2001) Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett 495:159-166. (Pubitemid 32397697)
46. Team RDC (2008) R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria).